Apellis Pharmaceuticals Inc (NAS:APLS)
$ 28.075 -0.485 (-1.7%) Market Cap: 3.49 Bil Enterprise Value: 3.59 Bil PE Ratio: 0 PB Ratio: 12.94 GF Score: 42/100

Apellis Pharmaceuticals Inc Virtual Investorm Meeting - Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) Transcript

Jan 28, 2021 / 03:00PM GMT
Release Date Price: $44.9 (+5.30%)
Operator

(Operator Instructions) It is now my pleasure to turn today's program over to Federico Grossi of Apellis Pharmaceuticals.

Federico Grossi
Apellis Pharmaceuticals, Inc. - Co-Founder & Chief Medical Officer

Thank you very much. Good morning, everyone, and welcome to Apellis Investor Event on Pegcetacoplan, Advancing the Treatment for Geographic Atrophy or GA. My name is Federico Grossi. I'm Apellis' Chief Medical Officer and will serve as the master of ceremony for today's event.

Next slide. Before we begin, I would like to make the point that we'll be making forward-looking statements that are based on the current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed on our SEC filings for additional details.

The next slide. We also want to make you aware of specific disclosures related to our speakers today.

So we're joined today -- the next slide, please. We're joined today by a lead of group

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot